Catumaxomab

Drug Profile

Catumaxomab

Alternative Names: Anti-CD3 anti-EpCAM monoclonal antibody; Anti-CD3 X anti-EpCAM; Removab

Latest Information Update: 19 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TRION Pharma
  • Developer Neovii Biotech; Swedish Orphan Biovitrum; TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Malignant ascites
  • Phase II Gastric cancer; Ovarian cancer
  • Phase I Carcinoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 10 Mar 2015 Catumaxomab is still in phase II trials for Ovarian cancer in the USA, Austria, Germany and Spain
  • 09 Mar 2015 No recent reports on development identified - Phase-II for Malignant ascites (Recurrent) in USA (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top